Author

C. Abecunas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:deep learning· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

M. Fallahi-Sichani· 2 shared A. D. Kidd· 1 shared C. Frankowski-McGregor· 1 shared C. Whitehead· 1 shared D. G. Baumann· 1 shared E. Ziemke· 1 shared H. Zong· 1 shared J. Sebolt-Leopold· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. Fallahi-Sichani

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Multivariate analysis of metabolic state vulnerabilities across diverse cancer contexts reveals synthetically lethal associations

C. Abecunas, A. D. Kidd, Y. Jiang, H. Zong, M. Fallahi-Sichani

The paper identifies metabolic state vulnerabilities in cancer cell lines and discovers synthetically lethal associations between metabolism, mutations, and therapeutic targets.

bioRxiv · Nov 28, 2023Cancer Biology

Systematic analysis uncovers SYK dependency in NF1LoF melanoma cells

C. Abecunas, C. Whitehead, E. Ziemke, D. G. Baumann, C. Frankowski-McGregor, J. Sebolt-Leopold, M. Fallahi-Sichani

This study identifies SYK as a therapeutic target in NF1LoF melanoma cells, showing that MTX-216, a compound inhibiting both PI3K and SYK, effectively blocks tumor growth.

bioRxiv · Mar 6, 2022Cancer Biology